Contributor Since 2009
OncoSil Medical (ASX: OSL) has appointed Nicholas Falzon as joint company secretary and financial controller as part of the transition in place at the company.
As a partner at Lawler Partners, Falzon works with a number of listed and unlisted companies advising them on all aspects of their financial management.
He specialises in Research and Development Tax Concessions and has been successful in identifying substantial potential savings for the company in the planned clinical trial for its pancreatic cancer treatment medical device OncoSil™.
In addition to his tax expertise, Falzon has extensive business management, corporate finance and compliance related experience.
Current company joint secretary and legal counsel Jillian McGregor has resigned.
OncoSil is developing OncoSil™ as an implantable device that emits radiation directly into the pancreatic tumour, and the pain conducting nerves surrounding it.
Radiation therapy, such as that supplied by OncoSil™ is known to kill tumour cells, and OncoSil™ delivers radiation therapy locally for up to three months. The device is inserted directly into the centre of the tumour using well established technology in a short 15-30 minute procedure.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.